Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleArticles on Covid-19

Selection of the Appropriate Control Group Is Essential in Evaluating the Cytokine Storm in COVID-19

ALICE G. VASSILIOU, IOANNA DIMOPOULOU, EDISON JAHAJ, CHRYSI KESKINIDOU, ZAFEIRIA MASTORA, STYLIANOS E. ORFANOS and ANASTASIA KOTANIDOU
In Vivo March 2021, 35 (2) 1295-1298; DOI: https://doi.org/10.21873/invivo.12381
ALICE G. VASSILIOU
1First Department of Critical Care Medicine & Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IOANNA DIMOPOULOU
1First Department of Critical Care Medicine & Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EDISON JAHAJ
1First Department of Critical Care Medicine & Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRYSI KESKINIDOU
1First Department of Critical Care Medicine & Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ZAFEIRIA MASTORA
1First Department of Critical Care Medicine & Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STYLIANOS E. ORFANOS
1First Department of Critical Care Medicine & Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece;
2Second Department of Critical Care, School of Medicine, National and Kapodistrian University of Athens, Attikon Hospital, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANASTASIA KOTANIDOU
1First Department of Critical Care Medicine & Pulmonary Services, School of Medicine, National and Kapodistrian University of Athens, Evangelismos Hospital, Athens, Greece;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: akotanid@med.uoa.gr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Lately, studies have reported contradicting results on the cytokine storm seen in critically-ill COVID-19 patients. Depending on the control group used, cytokines have been found to be higher, similar or even lower in COVID-19 compared to critical illnesses associated with elevated cytokine concentrations. However, most of these studies do not take into account critical illness severity. Hence, we decided to compare cytokine levels in critically-ill COVID-19 patients and critically-ill patients of a general intensive care unit (ICU), who did not have sepsis or septic shock, but had an equal disease severity. Patients and Methods: Interleukin (IL)-6, IL-8, IL-10 and tumour necrosis factor-α (TNF-α) were measured on ICU admission in mechanically ventilated, COVID-19 (N=36) and non-COVID-19 (N=30) patients, who had not received dexamethasone, and had equal critical illness severity. Non-COVID-19 patients did not have sepsis or septic shock. Results: In our case control study, circulating IL-6 and IL-10 were lower, while TNF-α and IL-8 levels were higher in critically-ill COVID-19 patients, compared to critically-ill non-COVID-19 patients. Conclusion: It is difficult to infer whether the cytokine storm seen in COVID-19 differs from other critical conditions. It is important to recognize that the conclusions of related studies may depend on control group selection.

  • COVID-19
  • cytokine storm
  • critically-ill
  • ICU

Excellent reports and meta-analyses are being published lately questioning the cytokine response seen in critically-ill COVID-19 patients. Depending on the comparison group used, results are contradicting. Interleukin (IL)-6 has been shown to be lower in critical COVID-19 compared to septic shock with or without ARDS (1, 2), and hypo- and hyper-inflammatory ARDS (3, 4), or similar to trauma patients (1); IL-8 has been shown to be lower in critical COVID-19 compared to septic shock with or without ARDS (1), and hyper-inflammatory ARDS, but similar to hypoinflammatory ARDS (3). Tumour necrosis factor-α (TNF-α) has been shown to be lower or similar to sepsis with or without ARDS, but higher compared to trauma (1, 3). Other cytokines, such as IL-10, have not been sufficiently investigated, while one report showed no differences between COVID-19 and sepsis in 76 cytokines (5). However, the above reports do not account for differences in critical illness severity, as expressed by the acute physiologic assessment and chronic health evaluation II (APACHE II). and sequential organ dysfunction assessment (SOFA) scores, do not take into account dexamethasone administration, or have compared cytokine levels measured by different platforms. Since it seems that the control group matters, we decided to compare cytokine levels in critically-ill COVID-19 patients and critically-ill patients of a general intensive care unit (ICU), who did not have sepsis or septic shock, but had an equal disease severity. None of the patients studied had received dexamethasone.

Patients and Methods

This prospective observational case control study was carried out in one academic multi-disciplinary ICU. All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki Declaration and its later amendments. The study was approved by the Hospital Research Ethics Committee (129/19-3-2020). Informed consent was obtained by patients’ next-of-kin. ICU admission (within 24 hours) serum concentrations of IL-6, IL-8, IL-10, and TNF-α were determined by ELISA (R&D Systems Inc., Minneapolis, MN, USA), by the same researcher, in 36 consecutive critically-ill COVID-19 patients and 30 consecutive critically-ill non-COVID-19 patients. SARS-CoV-2 infection was diagnosed by real-time reverse transcription PCR (RT-PCR) in nasopharyngeal swabs. The COVID-19 patients suffered from pneumonia and were directly admitted to the ICU of the Hospital, from March 22 to August 3 2020. Only patients receiving dexamethasone prior to blood sampling were excluded from the study. There were no other exclusion criteria. The critically-ill non-COVID-19 patients were a subset of a larger, previously studied, in a different non cytokine-related context, cohort of critically-ill patients (6). Patients with sepsis on or within the first 24 hours of ICU admission, no need for intubation, brain death, end-stage cancer, total ICU stay <3 days, re-admission or transfer from another ICU, contagious diseases, oral or inhaled intake of corticosteroids for a period of more than one month, and use of immunosuppressive medication were excluded.

Data were expressed as mean±standard deviation (SD) for normally distributed variables, median with interquartile range (IQR) for variables with skewed distribution and as count (%) when categorical. Two-group comparisons were performed using the Student’s t-test or the non-parametric Mann-Whitney test. Associations between qualitative variables were examined by the chi-square test. All aforementioned analyses were performed using the GraphPad software (San Diego, CA, USA). All p-values are two-sided; p<0.05 was considered statistically significant.

Results and Discussion

The critically-ill non-COVID-19 patients consisted of trauma (N=16), surgical (N=8) and medical (CNS-related pathologies, N=6) cases. As seen in Table I, there were no differences in disease severity between the two groups. COVID-19 patients exhibited the first symptoms 6±2 days prior to admission. In our cohort, circulating IL-6 and IL-10 were lower in critically-ill COVID-19 patients, while TNF-α and IL-8 levels were higher, compared to critically-ill non-COVID-19 patients (Table I and Figure 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient characteristics on ICU admission.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Cytokine levels in critically-ill COVID-19 and non-COVID-19 patients. IL-6 (A), IL-8 (B), IL-10 (C), and TNF-α (D) were measured on ICU admission in 36 critically-ill COVID-19 patients and 30 critically-ill non-COVID-19 patients. Two-group comparisons were performed using the non-parametric Mann-Whitney test for skewed data. Data are presented as scatter plots showing median and interquartile range. Line in the middle, median value; upper and lower lines, 25th to 75th centiles. *p<0.05, **p<0.01, ****p<0.0001. COVID-19: Coronavirus disease 19, IL: Interleukin, TNF-α: tumour necrosis factor-α.

In this report, not all cytokines measured in critically-ill COVID-19 patients were lower compared to critically-ill non-COVID-19 subjects with the same disease severity. These preliminary results agree only in part with those presented in the aforementioned recently published reports (1, 3-5). Overall, it seems that there is a complexity of cytokine responses in critically-ill patients. This could explain why treatments with anti-cytokine agents have failed in general ICU patients, despite the fact that in mixed ICU patients cytokine concentrations on ICU admission act as independent outcome predictors (7). While it is clear that in COVID-19 circulating cytokines are high, it remains currently unanswered whether their levels exceed those of other critically-ill patients. The results of studies have suggested that the term “cytokine storm” does not appropriately describe COVID-19-induced organ dysfunction (1-5). It is important to recognize that the conclusions of related studies may depend on control group selection. Critically-ill COVID-19 patients exhibit a hyper-inflammatory response and develop organ failures, but the underlying mechanisms have not been elucidated. As in other syndromes of critical illness, the role of elevated inflammatory cytokines in the pathobiology of COVID-19 remains unclear. It is of outmost importance to correctly recognise the subset of COVID-19 patients who might benefit from cytokine-targeting therapy, such as IL-6 inhibitors, or drugs that inhibit cytokine expression (8). Limitations of the current investigation include the single-centre nature of the study, the small sample size, and the fact that four cytokines were measured, capturing only a part of the whole picture.

Acknowledgements

This work was funded by the non-profit institute THORAX Research Centre for Intensive and Emergency Thoracic Medicine, Athens, Greece.

Footnotes

  • Authors’ Contributions

    AGV, EJ, CK and ZM collected specimens and data, designed and conducted experiments and drafted the manuscript; ID, SEO and AK supervised patient enrolment, oversaw the study, contributed to its design, and edited the manuscript. All Authors read and approved the final manuscript.

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors declare that there is no conflict of interest in regard to this study.

  • Received January 8, 2021.
  • Revision received January 20, 2021.
  • Accepted January 22, 2021.
  • Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Kox M,
    2. Waalders NJB,
    3. Kooistra EJ,
    4. Gerretsen J and
    5. Pickkers P
    : Cytokine levels in critically ill patients with covid-19 and other conditions. JAMA 324(15): 1565-1567, 2020. PMID: 3288065. DOI: 10.1001/jama.2020.17052
    OpenUrlCrossRef
  2. ↵
    1. Hutchings SD,
    2. Watchorn J,
    3. Trovato F,
    4. Napoli S,
    5. Mujib SF,
    6. Hopkins P and
    7. McPhail M
    : Microcirculatory, endothelial and inflammatory responses in critically ill patients with covid-19 are distinct from those seen in septic shock: A case control study. Shock, 2020. PMID: 33021572. DOI: 10.1097/SHK.0000000000001672
    OpenUrlCrossRef
  3. ↵
    1. Leisman DE,
    2. Ronner L,
    3. Pinotti R,
    4. Taylor MD,
    5. Sinha P,
    6. Calfee CS,
    7. Hirayama AV,
    8. Mastroiani F,
    9. Turtle CJ,
    10. Harhay MO,
    11. Legrand M and
    12. Deutschman CS
    : Cytokine elevation in severe and critical covid-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med 8(12): 1233-1244, 2020. PMID: 33075298. DOI: 10.1016/S2213-2600(20)30404-5
    OpenUrlCrossRef
  4. ↵
    1. Sinha P,
    2. Matthay MA and
    3. Calfee CS
    : Is a “cytokine storm” relevant to covid-19? JAMA Intern Med 180(9): 1152-1154, 2020. PMID: 32602883. DOI: 10.1001/jamainternmed.2020.3313
    OpenUrlCrossRefPubMed
  5. ↵
    1. Wilson JG,
    2. Simpson LJ,
    3. Ferreira AM,
    4. Rustagi A,
    5. Roque J,
    6. Asuni A,
    7. Ranganath T,
    8. Grant PM,
    9. Subramanian A,
    10. Rosenberg-Hasson Y,
    11. Maecker HT,
    12. Holmes SP,
    13. Levitt JE,
    14. Blish CA and
    15. Rogers AJ
    : Cytokine profile in plasma of severe covid-19 does not differ from ards and sepsis. JCI Insight 5(17): e140289, 2020. PMID: 32706339. DOI: 10.1172/jci.insight.140289
    OpenUrlCrossRef
  6. ↵
    1. Vassiliou AG,
    2. Mastora Z,
    3. Orfanos SE,
    4. Jahaj E,
    5. Maniatis NA,
    6. Koutsoukou A,
    7. Armaganidis A and
    8. Kotanidou A
    : Elevated biomarkers of endothelial dysfunction/activation at icu admission are associated with sepsis development. Cytokine 69(2): 240-247, 2014. PMID: 25016133. DOI: 10.1016/j.cyto.2014.06.010
    OpenUrlCrossRefPubMed
  7. ↵
    1. Dimopoulou I,
    2. Orfanos S,
    3. Kotanidou A,
    4. Livaditi O,
    5. Giamarellos-Bourboulis E,
    6. Athanasiou C,
    7. Korovesi I,
    8. Sotiropoulou C,
    9. Kopterides P,
    10. Ilias I,
    11. Kanellakopoulou K and
    12. Armaganidis A
    : Plasma pro- and anti-inflammatory cytokine levels and outcome prediction in unselected critically ill patients. Cytokine 41(3): 263-267, 2008. PMID: 18191577. DOI: 10.1016/j.cyto.2007.11.019
    OpenUrlCrossRefPubMed
  8. ↵
    1. Pollard BS,
    2. Blanco JC and
    3. Pollard JR
    : Classical drug digitoxin inhibits influenza cytokine storm, with implications for covid-19 therapy. In Vivo 34(6): 3723-3730, 2020. PMID: 33144490. DOI: 10.21873/invivo.12221
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

In Vivo: 35 (2)
In Vivo
Vol. 35, Issue 2
March-April 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Selection of the Appropriate Control Group Is Essential in Evaluating the Cytokine Storm in COVID-19
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Selection of the Appropriate Control Group Is Essential in Evaluating the Cytokine Storm in COVID-19
ALICE G. VASSILIOU, IOANNA DIMOPOULOU, EDISON JAHAJ, CHRYSI KESKINIDOU, ZAFEIRIA MASTORA, STYLIANOS E. ORFANOS, ANASTASIA KOTANIDOU
In Vivo Mar 2021, 35 (2) 1295-1298; DOI: 10.21873/invivo.12381

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Selection of the Appropriate Control Group Is Essential in Evaluating the Cytokine Storm in COVID-19
ALICE G. VASSILIOU, IOANNA DIMOPOULOU, EDISON JAHAJ, CHRYSI KESKINIDOU, ZAFEIRIA MASTORA, STYLIANOS E. ORFANOS, ANASTASIA KOTANIDOU
In Vivo Mar 2021, 35 (2) 1295-1298; DOI: 10.21873/invivo.12381
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results and Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Experience of Greece as a Model to Contain COVID-19 Infection Spread
  • Colorectal Cancer Surgery During the COVID-19 Pandemic: A Single Center Experience
Show more Articles on Covid-19

Similar Articles

Keywords

  • COVID-19
  • cytokine storm
  • critically-ill
  • ICU
In Vivo

© 2023 In Vivo

Powered by HighWire